Latest Haemophilia Stories

NASHVILLE, Tenn., Dec. 10, 2011 /PRNewswire/ -- Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K. To view the multimedia assets associated with this release, please click:...

KING OF PRUSSIA, Pa., Dec. 2, 2011 /PRNewswire/ -- CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders. CSL Behring has awarded more than $600,000 in grants...

LAGUNA NIGUEL, Calif., Nov. 28, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program. In the newly initiated clinical study, OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, will be evaluated for the treatment of individuals with congenital hemophilia A who have developed inhibitory antibodies...

CHICAGO, Nov. 11, 2011 /PRNewswire/ -- At a special ceremony at the National Hemophilia Foundation (NHF) Annual Meeting in Chicago, Bayer HealthCare and members of the hemophilia community commemorated the successful conclusion of Bayer's first Virtual Walk for Hemophilia (www.walkforhemophilia.com), an innovative interactive contest that raises awareness and funds for those living with a bleeding disorder. Bayer also kicked off year two of the Virtual Walk as a means of continued support...

(Ivanhoe Newswire) – A new drug commonly used to treat bleeding events in people with severe hemophilia can also be used to prevent such events from happening at all, according to this study. An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, examined the ability of FEIBA to prevent bleeds in people with severe hemophilia A with inhibitors. People with this condition produce...

HOBOKEN, N.J., Nov. 7, 2011 /PRNewswire/ -- The Journal of Thrombosis and Haemostasis has published the results of the first prospective, head-to-head, randomized crossover clinical study to compare the pharmacokinetic (PK) profiles of two VWF/FVIII containing Von Willebrand Disease (VWD) products. The study compared the PK profiles of wilate® (Von Willebrand Factor/Factor VIII Concentrate, Human) and Humate-P® Human Plasma-derived Von Willebrand Factor (HP-VWF/FVIII) Concentrate. As...

For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients. Researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine, collaborating with other institutions, report in Experimental Hematology that a single injection of genetically-modified adult stem cells in two...

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place. The study, the first to confirm the efficacy and safety of the drug FEIBA™ in bleed prevention is published in the Nov. 3, 2011 issue of the New...

Children's Hospital of Philadelphia study suggests strategy to bypass defect in hemophilia, may also benefit other bleeding disorders A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems. The researchers took the naturally occurring coagulation factor Xa (FXa), a protein active in blood clotting, and engineered it into a novel variant that safely...

KING OF PRUSSIA, Pa., Oct. 20, 2011 /PRNewswire/ -- CSL Behring announces publication of its Key Issues Dialogue on "Access to Care" which addresses many of the practices that impede access to care for people with rare and serious medical disorders, and possible solutions. This discussion is especially relevant now as healthcare reform is being implemented to assure that people with rare diseases do not end up with reduced care as an unintended consequence. (Logo:...